Limited peritoneal disease progression in gastric cancer patients: No survival benefit with gastrectomy + cytoreductive surgery and HIPEC
The study aimed to evaluate the impact of gastrectomy with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the outcomes of gastric cancer (GC) patients with limited peritoneal disease progression following neoadjuvant chemotherapy (NAC). Results showed that there was no survival benefit among advanced GC patients with peritoneal metastasis (PM) who underwent gastrectomy with CRS+HIPEC compared to those who underwent gastrectomy with CRS alone.
In patients with gastric cancer and positive peritoneal lavage cytology or localized peritoneal metastasis, upfront chemotherapy followed by surgery yields better outcomes than surgery followed by chemotherapy.
Secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy improves survival for select patients with recurrent colorectal cancer peritoneal metastases.
